BioPharmSignal logoBioPharmSignal

Biotech News

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

Sight Sciences (SGHT)Sight SciencesEarnings

MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today

Related news

SGHTSight Sciences2026-07-22 20:05 EST

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

TARSTarsus Pharmaceuticals2026-08-06 00:03 EST

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

TMCITreace Medical Concepts2026-07-24 11:05 EST

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

OMOutset Medical2026-07-23 13:00 EST

Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

IRTCiRhythm2026-07-16 20:05 EST

iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026

View all latest news

Sight Sciences

Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a...

Recent company news

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

SGHTSight Sciences2026-08-05 20:04 EST

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

SGHTSight Sciences2026-07-22 20:05 EST

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

Stock data

Close
7.09 USD
Market cap
236.14M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States